sara m. tolaney, md, mph on whether cdk4/6 inhibitors can be used interchangeably
Published 6 years ago • 26 plays • Length 1:58
Download video MP4
Download video MP3
Similar videos
-
1:54
sara m. tolaney, md, mph, shares outcomes from the monaleesa-7 trial
-
2:07
remaining questions regarding the use of frontline cdk4/6 inhibitors and endocrine therapy
-
1:00
dr. tolaney on remaining questions with cdk4/6 inhibitors in hr /her2- breast cancer
-
2:02
sara m. tolaney, md, mph, on the efficacy & safety of combination eribulin pembrolizumab
-
6:55
additional advances in triple-negative breast cancer research and trials: sara m. tolaney, md, mph
-
1:41
dana-farber cancer institute | sara tolaney, md, mph, at sabcs 2020
-
1:38
sara m. tolaney, md, mph, discusses the fulvestrant ribociclib arm of the monaleesa-3 study
-
1:49
sabcs22: sara tolaney, md, mph | dana-farber cancer institute
-
1:02:24
at the leading edge of breast cancer research: immuno-oncology
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
1:54
cell cycle inhibitors - cdk4/6 inhibitors
-
5:34
cdk4/6 inhibitors in metastatic breast cancer
-
1:48
sara m. tolaney, md, mph discusses the tailorx study
-
1:45
asco23: sara tolaney, md, mph | dana-farber cancer institute
-
14:40
cdk4/6i in hr sabcs 2022 highlights - oncbrothers (rohit and rahul gosain) with dr. sara tolaney
-
5:38
cdk4/6 inhibitors in metastatic breast cancer
-
1:10
sara m. tolaney, md, mph tells us about the outcomes of the monarch 2 study
-
5:38
cdk4/6 inhibitors in metastatic breast cancer
-
3:13
sara tolaney md, mph shares results from the phase 2 atempt trial at sabcs 2019
-
1:55
sara m. tolaney, md, mph, shares outcomes from the impassion130 study in tnbc
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
Clip.africa.com - Privacy-policy